Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking innovations like mRNA cancer vaccines and CRISPR-based therapies. Structural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback